Skip to main
BBNX
BBNX logo

BBNX Stock Forecast & Price Target

BBNX Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 56%
Buy 33%
Hold 11%
Sell 0%
Strong Sell 0%

Bulls say

Beta Bionics Inc. demonstrated strong financial performance in Q3'25, reporting revenue of $27.3 million, reflecting a substantial year-over-year growth of 63.3%, exceeding estimates by $3.8 million. The company has also raised its fiscal year 2025 revenue guidance to exceed $96.5 million, suggesting positive momentum in sales driven by new patient starts and an increasing portion of revenue coming from the pharmacy channel, which generates significantly higher margins. Furthermore, the upward revisions in revenue estimates for 2025 and 2026, now projected at $97.5 million and $136 million respectively, underscore a robust outlook for top-line growth in the coming years, supported by successful expansion efforts and a rising market share in the insulin pump sector.

Bears say

Beta Bionics faces significant risks that could negatively impact its financial outlook, including challenges in gaining market share for its iLet product amidst competitive pressures and difficulties in establishing pharmacy channel penetration, which may lead to downward revisions in revenue and profitability estimates. The company is also contending with potential delays in clinical development and the lack of FDA marketing approval for Type 2 diabetes, diminishing its competitive edge compared to peers. Additionally, a projected EBITDA loss of $12.2 million, which exceeded previous estimates, combined with the need for additional capital that might lead to shareholder dilution, further complicates Beta Bionics's financial situation moving forward.

BBNX has been analyzed by 9 analysts, with a consensus rating of Buy. 56% of analysts recommend a Strong Buy, 33% recommend Buy, 11% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Beta Bionics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Beta Bionics Inc (BBNX) Forecast

Analysts have given BBNX a Buy based on their latest research and market trends.

According to 9 analysts, BBNX has a Buy consensus rating as of Nov 26, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $28.22, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $28.22, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Beta Bionics Inc (BBNX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.